Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;44(7):978-986.
doi: 10.1002/clc.23630. Epub 2021 May 19.

Clinical implication of quantitative flow ratio to predict clinical events after drug-coated balloon angioplasty in patients with in-stent restenosis

Affiliations

Clinical implication of quantitative flow ratio to predict clinical events after drug-coated balloon angioplasty in patients with in-stent restenosis

Jiani Tang et al. Clin Cardiol. 2021 Jul.

Abstract

Background: The association between the quantitative flow ratio (QFR) and adverse events after drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR) lesions has not been investigated.

Hypothesis: Post-procedural QFR is related to adverse events in patients undergoing DCB angioplasty for ISR lesions.

Methods: This retrospective study included data from patients undergoing DCB angioplasty for drug-eluting stent (DES) ISR between January 2016 and February 2019. The QFR was measured at baseline and after DCB angioplasty. The endpoint was the vessel-oriented composite endpoint (VOCE), defined as a composite of cardiac death, vessel-related myocardial infarction, and ischemia-driven target vessel revascularization.

Results: Overall, 177 patients with 185 DES-ISR lesions were included. During 1-year follow-up, 27 VOCEs occurred in 26 patients. The area under curve (AUC) of the post-procedural QFR was statistically greater than that of the in-stent percent diameter stenosis (0.77, 95% confidence interval [CI] 0.67-0.87 vs. 0.64, 95% CI 0.53-0.75; p = .032). Final QFR cutoff of 0.94 has the best predictive accuracy for VOCE. A QFR > 0.94 was associated with a lower risk of VOCE compared to a QFR ≤ 0.94 (log-rank test, p < .0001). Survival analysis using the multivariable Cox model showed that a post-procedural QFR ≤ 0.94 was an independent predictor of 1-year VOCE (hazard ratio 6.53, 95% CI 2.70-15.8, p < .001).

Conclusions: A lower QFR value was associated with worse clinical outcomes at 1 year after DCB angioplasty for DES-ISR.

Keywords: drug-coated balloon; percutaneous coronary intervention; quantitative flow ratio.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Case example of reconstructed 3‐D QCA and measured QFR. QFR calculation was based on the 3D‐QCA reconstructed from two angiographic projections with angles ≥25 ° apart and 3D reconstruction of the interrogated vessel without its side branches was performed. (A) Pre‐procedural angiographic image shows a ISR lesion, and QFR was 0.70 (B) Final angiography showed minimal residual stenosis after DCB treatment, and QFR was 0.96. Red arrows indicate the target ISR lesion. DCB, drug‐coated balloon; ISR, in‐stent restenosis; QCA, quantitative coronary angiography; QFR, quantitative flow ratio
FIGURE 2
FIGURE 2
(A) Receiver operator characteristic curves for the VOCE. The red line corresponds to the QFR value (AUC 0.77, 95% CI 0.67–0.87) and the green line to the in‐stent %DS (AUC 0.64, 95% CI 0.53–0.75). (B) Kaplan–Meier curves of VOCE occurrence at 1‐year follow‐up according to the post‐procedural QFR. AUC, area under curve; CI, confidence interval; %DS, percent diameter stenosis; QFR, quantitative flow ratio; VOCE, vessel‐oriented composite endpoint

Similar articles

Cited by

References

    1. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus‐ and paclitaxel‐eluting coronary stents. N Engl J Med. 2007;356:998‐1008. - PubMed
    1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus‐eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773‐1780. - PubMed
    1. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in‐stent restenosis. J Am Coll Cardiol. 2014;63:2659‐2673. - PubMed
    1. Alfonso F, Scheller B. State of the art: balloon catheter technologies‐drug‐coated balloon. EuroIntervention. 2017;13:680‐695. - PubMed
    1. Haybar H, Shahrabi S, Rezaeeyan H, Shirzad R, Saki N. Endothelial cells: from dysfunction mechanism to pharmacological effect in cardiovascular disease. Cardiovasc Toxicol. 2019;19:13‐22. - PubMed

Substances

LinkOut - more resources